Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 1/20 | 0.61 |
| ▸ | WDR5 | P61964 | 12/20 | 0.56 |
| ▸ | PTGIR | P43119 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28904914 | 0.83 | PTGIR (0.64) | WDR5PTGIRADRA2AADRA2BADRA2C | |
| SCHEMBL13063072 | 0.82 | WDR5 (0.55) | WDR5PTGIRNISCH | |
| SCHEMBL6132016 | 0.80 | WDR5 (0.62) | WDR5PTGIRKDM4EALDH1A1GAA | |
| SCHEMBL6666027 | 0.79 | WDR5 (0.65) | WDR5PTGIRADRA2AADRA2BADRA2C | |
| SCHEMBL17188814 | 0.79 | WDR5 (0.56) | WDR5PTGIRGAA | |
| SCHEMBL6300545 | 0.79 | WDR5 (0.53) | WDR5PTGIRADRA2AADRA2BADRA2C | |
| SCHEMBL3169468 | 0.78 | PTGIR (0.60) | WDR5PTGIRADRA2AADRA2BADRA2C | |
| SCHEMBL11764088 | 0.76 | PTGIR (0.69) | PTGIRADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL13063330 | 0.76 | CYP2D6 (0.58) | WDR5PTGIRADRA2AADRA2BADRA2C | |
| SCHEMBL10054979 | 0.76 | PTGIR (0.69) | WDR5PTGIRADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296958-A4 | IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002000629-A9 | IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-1296958-A1 | IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6440976-B2 | FOR THERAPY OF PAIN, MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, STROKE, AND IN THERAPY OF NEUROPATHIES INCLUDING POSTHERPETIC NEURALGIA, CENTRAL PAIN FROM SPINAL CORD INJURY, AND PHANTOM LIMB PAIN | MERCK & CO., INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020013329-A1 | Iminopyrimidine NMDA NR2B receptor antagonists | MERCK & CO., INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2002000629-A1 | IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013329-A1 | Iminopyrimidine NMDA NR2B receptor antagonists | GRIN1, GRIN2B, GRIN2C | HTR1B 56/4885WDR5 2268/4885PTGIR 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.